Related Experiment Video
Updated: Mar 28, 2026
Cecal Ligation Puncture Procedure
Published on: May 7, 2011
Sepsis-induced cardiomyopathy: mechanisms, epidemiology, diagnosis, and treatments
Fei Cao1, Tao Yan1, Chaoyue Liang2
1Department of Critical Care Medicine, Baotou Central Hospital, Baotou, Inner Mongolia, China.
Insights
Sepsis-induced cardiomyopathy (SICM) involves reversible heart dysfunction due to sepsis. Understanding its complex causes, diagnosis, and treatments is crucial for improving patient survival rates.
Area of Science:
- Cardiology
- Critical Care Medicine
- Pathophysiology
Background:
- Sepsis-induced cardiomyopathy (SICM) is a critical complication of sepsis, marked by reversible myocardial dysfunction.
- Its development involves intricate inflammatory, oxidative stress, and mitochondrial pathways, impacting cardiac function and survival.
- Demographic factors like age and sex, alongside pre-existing conditions, influence SICM risk.
Purpose of the Study:
- To review the current understanding of sepsis-induced cardiomyopathy.
- To identify knowledge gaps and propose future research directions for improved patient outcomes.
Main Methods:
- Literature synthesis of existing research on SICM.
- Analysis of epidemiological data, diagnostic methods, and therapeutic strategies.
- Review of historical perspectives and future research priorities.
Main Results:
- SICM pathophysiology is complex, involving inflammation, oxidative stress, and mitochondrial dysfunction.
- Diagnosis utilizes biomarkers and advanced imaging, but standardized criteria are lacking.
- Treatment options range from medications like levosimendan to mechanical support and novel therapies.
Conclusions:
- SICM is a significant factor in sepsis mortality, necessitating further research.
- Future directions include personalized medicine, multi-omics integration, and targeted therapies for SICM.
- Addressing research gaps is vital for enhancing patient outcomes in sepsis-induced cardiomyopathy.
Abstract:
Sepsis-induced cardiomyopathy (SICM) is a life-threatening complication of sepsis characterized by reversible myocardial dysfunction. Its pathophysiology involves a complex interplay of inflammatory pathways, oxidative stress, mitochondrial dysfunction, and genetic factors, leading to impaired cardiac contractility, ventricular dilatation, and increased mortality. Epidemiologically, SICM exhibits demographic variations, with younger age, male sex, and pre-existing heart failure identified as key risk factors. Diagnostic approaches rely on a combination of biomarkers (e.g., troponins, NT-proBNP), advanced imaging techniques (e.g., speckle-tracking echocardiography), and clinical criteria, though standardized definitions remain elusive. Treatment strategies include pharmacological interventions (e.g., levosimendan, melatonin), mechanical circulatory support (e.g., VA-ECMO, Impella), and emerging therapies targeting ferroptosis or mitochondrial function. Historical perspectives highlight the evolution from recognizing SICM as a rare complication to its current status as a major contributor to sepsis mortality, while future directions emphasize personalized medicine, multi-omics integration, and targeted therapeutics. This review synthesizes current knowledge of SICM, identifies critical gaps, and proposes actionable research priorities to improve patient outcomes.
Related Concept Videos
01:25Cardiomyopathy I: Introduction and Classification
01:29Cardiomyopathy V: Interprofessional Care
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:21Myocarditis I: Introduction
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:14Myocarditis III: Medical Management